Mapi Pharma
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Focus
Our main focus is on developing long acting depot injectable drugs.
Programs
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Latest News
Mapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine Depot
NESS ZIONA, Israel – Aug. 12, 2026 – Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced initial clinical results from its on-going Phase I/IIa trial that support...
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions Company is seeking partnerships for the most advanced long-acting depot injections in its pipeline, including Anastrozole Depot and Semaglutide Depot NESS ZIONA, Israel – June 1,...
Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for the Treatment of Primary Progressive Multiple Sclerosis.
Tuesday, March 3, 2026 | 11:00 AM ET